Miller JH - Search Results

1

Resistance to peloruside A and laulimalide: functional significance of acquired βI-tubulin mutations at sites important for drug-tubulin binding.

Kanakkanthara A, Eras J, Northcote PT, Cabral F, Miller JH. Kanakkanthara A, et al. Among authors: miller jh. Curr Cancer Drug Targets. 2014;14(1):79-90. doi: 10.2174/1568009613666131113101151. Curr Cancer Drug Targets. 2014. PMID: 24245693

2

Mycalamide D, a new cytotoxic amide from the New Zealand marine sponge Mycale species.

West LM, Northcote PT, Hood KA, Miller JH, Page MJ. West LM, et al. Among authors: miller jh. J Nat Prod. 2000 May;63(5):707-9. doi: 10.1021/np9904511. J Nat Prod. 2000. PMID: 10843597

3

Induction of apoptosis by the marine sponge (Mycale) metabolites, mycalamide A and pateamine.

Hood KA, West LM, Northcote PT, Berridge MV, Miller JH. Hood KA, et al. Among authors: miller jh. Apoptosis. 2001 Jun;6(3):207-19. doi: 10.1023/a:1011340827558. Apoptosis. 2001. PMID: 11388670

4

The novel cytotoxic sponge metabolite peloruside A, structurally similar to bryostatin-1, has unique bioactivity independent of protein kinase C.

Hood KA, Bäckström BT, West LM, Northcote PT, Berridge MV, Miller JH. Hood KA, et al. Among authors: miller jh. Anticancer Drug Des. 2001 Apr-Jun;16(2-3):155-66. Anticancer Drug Des. 2001. PMID: 11962513

5

Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule- stabilizing activity.

Hood KA, West LM, Rouwé B, Northcote PT, Berridge MV, Wakefield SJ, Miller JH. Hood KA, et al. Among authors: miller jh. Cancer Res. 2002 Jun 15;62(12):3356-60. Cancer Res. 2002. PMID: 12067973

6

Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines.

Gaitanos TN, Buey RM, Díaz JF, Northcote PT, Teesdale-Spittle P, Andreu JM, Miller JH. Gaitanos TN, et al. Among authors: miller jh. Cancer Res. 2004 Aug 1;64(15):5063-7. doi: 10.1158/0008-5472.CAN-04-0771. Cancer Res. 2004. PMID: 15289305

7

Peloruside A enhances apoptosis in H-ras-transformed cells and is cytotoxic to proliferating T cells.

Miller JH, Rouwé B, Gaitanos TN, Hood KA, Crume KP, Bäckström BT, La Flamme AC, Berridge MV, Northcote PT. Miller JH, et al. Apoptosis. 2004 Nov;9(6):785-96. doi: 10.1023/B:APPT.0000045789.54694.cf. Apoptosis. 2004. PMID: 15505421

8

Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly.

Hamel E, Day BW, Miller JH, Jung MK, Northcote PT, Ghosh AK, Curran DP, Cushman M, Nicolaou KC, Paterson I, Sorensen EJ. Hamel E, et al. Among authors: miller jh. Mol Pharmacol. 2006 Nov;70(5):1555-64. doi: 10.1124/mol.106.027847. Epub 2006 Aug 3. Mol Pharmacol. 2006. PMID: 16887932

9

Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines.

Wilmes A, Bargh K, Kelly C, Northcote PT, Miller JH. Wilmes A, et al. Among authors: miller jh. Mol Pharm. 2007 Mar-Apr;4(2):269-80. doi: 10.1021/mp060101p. Mol Pharm. 2007. PMID: 17397239

10

Peloruside A, an antimitotic agent, specifically decreases tumor necrosis factor-alpha production by lipopolysaccharide-stimulated murine macrophages.

Crume KP, Miller JH, La Flamme AC. Crume KP, et al. Among authors: miller jh. Exp Biol Med (Maywood). 2007 May;232(5):607-13. Exp Biol Med (Maywood). 2007. PMID: 17463156

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

980 results

Search Page

Filters